Lipid-based Cancer Therapeutics

基于脂质的癌症治疗

• 批准号: 10415232
• 负责人: Johannes Morstein
• 金额: $ 8.6万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10415232
• 关键词: Antineoplastic Agents; Biological; Biological Products; Biology; Cancer Biology; Cell Culture Techniques; Cell membrane; Chemistry; Clinical; Clinical Trials; Complement; Conceptions; Development; Doxorubicin Hydrochloride Liposome; Encapsulated; Enzymes; Goals; Human; In Vitro; Interdisciplinary Study; Ion Channel; KRAS2 gene; Knowledge; Light; Lipids; Malignant Neoplasms; Medicine; Membrane Proteins; Mutate; Oncogenes; Optics; Pharmaceutical Preparations; Pharmacology; Postdoctoral Fellow; Property; Research; Research Project Grants; Signal Transduction; Small RNA; Surface; System; Tail; Therapeutic; base; cancer immunotherapy; cancer therapy; clinical efficacy; design; improved; innovation; lipid metabolism; lipid nanoparticle; nanotherapy; novel; novel strategies; pharmacophore; receptor; small molecule; therapeutic RNA

Project Summary Significant progress in human cancer therapy in the last decade has been driven by conceptionally new approaches to targeting cancer, including cancer immunotherapy, cancer nanotherapy, or new types of biologics and small molecules. Both my dissertation and postdoc research will be focused on the development of fundamentally new approaches to targeting cancer. My dissertation research is focused on the development of photoswitchable lipids for the optical control of lipid metabolism and function. In addition to targeting specific receptors, ion-channels, or enzymes, light-induced structural changes in a lipid nanoparticle (LNP) could serve as trigger for the release of encapsulated drugs. Triggered release could markedly improve the efficacy of clinically approved LNP-based cancer therapeutics, which include Doxil/Caelyx, DaunoXome, Myocet, Lipo-Dox, or Marqibo. I seek to design and synthesize photoswitchable lipids for `photoactivable lipid nanoparticles', herein termed paLNPs, that allow for effective light- triggered release of encapsulated cancer drugs. Two complementary approaches will be developed for small molecule drugs and RNA-based therapeutics and the pharmacological properties of paLNPs will be systematically investigated in vitro and in cell culture. In my postdoctoral research I seek to use my acquired knowledge in chemistry, lipid-biology, and medicine to develop lipid-drug conjugates for biological targets that function at plasma-membrane signaling hotspots. The initial target will be the mutated oncogene KRAS G12C, which is ideally suited for this new approach. Conjugating selective covalent modifier of this oncogene with a lipid will attach an additional lipid tail to the surface of KRAS that could largely alter its membrane-protein interaction and in the best case completely inhibit its function. This could markedly increase the efficacy of the covalent pharmacophores currently in clinical trials. I seek to synthesize and systematically study these lipid-drug conjugates in vitro and in cell culture.

项目摘要 在过去十年中，人类癌症治疗的重大进展是由概念上的新驱动的 靶向癌症的方法，包括癌症免疫疗法，癌症纳米疗法或新型生物制剂 和小分子。我的论文和博士后研究都将集中于 从根本上讲，靶向癌症的新方法。 我的论文研究的重点是开发可拍摄脂质的脂质的光学控制 代谢和功能。除了靶向特定受体，离子通道或酶外，光诱导 脂质纳米颗粒（LNP）的结构变化可以作为释放封装药物的触发。 触发的释放可以显着提高临床认可的基于LNP的癌症治疗剂的功效， 其中包括Doxil/Caelyx，Daunoxome，Myocet，Lipo-Dox或Marqibo。我寻求设计和合成 本文称为palnps的“光活化脂质纳米颗粒”的可照相脂质，可有效光 - 触发了封装的癌症药物的释放。小型将开发两种互补方法 分子药物和基于RNA的疗法以及PALNP的药理特性将是 系统地研究了体外和细胞培养。 在博士后研究中，我试图利用我在化学，脂质生物学和医学方面获得的知识 开发用于在等离子体膜信号热点功能的生物学靶标的脂质 - 毒物结合物。这 最初的目标将是突变的Oncogene KRAS G12C，非常适合这种新方法。共轭 使用脂质的这种癌基因的选择性共价修饰者将附加脂质尾巴附加到Kras表面 这可能会在很大程度上改变其膜 - 蛋白质相互作用，在最好的情况下，这完全可以完全抑制其功能。这 可以显着提高目前在临床试验中的共价药理的疗效。我寻求 合成并系统地研究这些脂质 - 毒物结合物在体外和细胞培养中。